
Ataxia Clinical Trial Progresses to 48-Week Extension Phase
BIOHAVEN OPTIMISTIC FOR NEXT PHASE OF TRIAL DESPITE DISAPPOINTING TOPLINE DATA As NAF previously reported, BioHaven Pharmaceutical Holding Company Ltd. recently completed its 8-week trial of Read More…



